Issue #48July 27, 20267 studies

Psychedelics during adolescence reshaped adult social behavior in rats — here's the circuit

Psychedelic research had a productive week — new mechanisms, a cleaner drug candidate, and a sobering reminder that timing matters.

From rat brains to human stem cells, the science is getting more specific about what these compounds actually do, and when they do it.

🧠 Teen Psychedelic Exposure Left Lasting Social Scars in Rats

Rats given the potent psychedelic 25C-NBOMe repeatedly during adolescence — but not adulthood — developed lasting competitive avoidance: they consistently backed down from social competition, a behavior that persisted into adulthood.
Brain recordings pinpointed the problem: reduced theta-wave synchrony between the ventral hippocampus and orbitofrontal cortex, two regions that coordinate social decision-making.
The clincher — chemogenetically activating that same hippocampus-to-orbitofrontal pathway reversed the avoidance behavior in drug-exposed rats, while blocking it in healthy rats produced the same avoidance from scratch.

Why it matters: This isn't just a behavioral observation. The study identified a specific circuit, disrupted it, and rescued it — which makes the adolescent timing window harder to dismiss as a footnote.

🥇 Top 1% journal 🔗 Nature neuroscience 🗓️ Jul 20

Key Findings

🔬 A New Psychedelic Compound Skips the Nausea

Researchers built VCU-1012, a modified version of the psychedelic quipazine, engineered to activate serotonin-2A receptors without also triggering serotonin-3 receptors — the off-target hit responsible for gastrointestinal side effects.
In mice, VCU-1012 produced antidepressant-like effects and promoted structural changes in frontal cortex neurons, without the gut-related side effects that make quipazine a messier option.

💡 A cleaner side-effect profile, by design rather than accident.

🥉 Top 5% journal 🔗 Science signaling 🗓️ Jul 21

💉 MDMA After Trauma Reduced PTSD-Like Symptoms in Rats — But Dose and Timing Were Everything

In 175 male rats exposed to predator scent stress, a 10 mg/kg dose of MDMA given 30 minutes after trauma significantly reduced anxiety-like behavior, startle responses, and contextual freezing one week later — lower doses did not.
When MDMA was delayed 24 hours, it only worked when paired with a trauma-related cue, suggesting the drug needs to interact with active memory consolidation to be effective.

💡 Timing and context determined whether MDMA helped or did nothing at all.

🔗 Progress in neuro-psychopharmacology & biological psychiatry 🗓️ Jul 24

🧬 Ketamine and Psychedelics Converge on the Same Molecular Pathways in Human Neurons

Using stem-cell-derived neurons from people with treatment-resistant depression and healthy volunteers, researchers treated cells with ketamine metabolites, psilocybin, LSD, and a related compound — and found that despite hitting different initial targets, all four drugs produced highly correlated gene expression changes, converging on inflammation, cellular growth, and a key growth-signaling pathway.
A ketamine metabolite showed one distinctive pattern: it boosted activity in excitatory neurons while simultaneously suppressing inhibitory ones — a cell-type split the other drugs didn't replicate.

💡 Different drugs, same downstream destination — with at least one meaningful exception.

🥈 Top 2% journal 🔗 Molecular psychiatry 🗓️ Jul 24

🐭 Social Rank Determined Who Got Hit Hardest by Chronic Stress — and Who Responded to Ketamine

In group-housed male mice tracked continuously over 11 days, dominant individuals showed the most pronounced behavioral disruption after chronic stress — including fragmented rest and reduced social interaction — while subordinates were comparatively buffered.
A single ketamine dose restored baseline behavior specifically in dominant stressed mice, and triggered a distinct set of 141 differentially expressed genes in their prefrontal cortex.

💡 Social rank quietly predicted both stress vulnerability and drug response.

🎖️ Top 10% journal 🔗 iScience 🗓️ Jul 24

💊 Real-World Ketamine Clinics Are Filling a Gap — With Limited Oversight Data

A retrospective look at a community clinic offering both intravenous ketamine and intranasal esketamine found real-world outcomes for treatment-resistant depression patients, adding observational evidence to a field dominated by tightly controlled trials.
The study flags a persistent blind spot: controlled trial populations don't always reflect who actually walks into a community clinic, making it harder to know how well efficacy data translates.

💡 Clinic data and trial data aren't the same thing, and the gap is growing.

Top 20% journal 🔗 Frontiers in psychiatry 🗓️ Jul 24

🌿 BC's Drug Decriminalization Pilot Ended — and the Implementation Story Is Complicated

British Columbia's 2023 pilot — which removed criminal penalties for possessing up to 2.5 g of opioids, cocaine, methamphetamine, and MDMA — was reversed in public spaces by May 2024 and fully ended in January 2026, a timeline that made clean outcome assessment nearly impossible.
A systematic review found that implementation factors, not just the policy itself, shaped early outcomes, meaning the pilot's end tells us more about how decriminalization was rolled out than whether the underlying idea works.

💡 Policy failure and implementation failure are not the same verdict.

🎖️ Top 10% journal 🔗 The International journal on drug policy 🗓️ Jul 21

Implications

The adolescent brain circuit finding and the stem-cell convergence data point in the same uncomfortable direction: these compounds are pharmacologically precise enough to study rigorously, but the variables that determine benefit versus harm — age, dose, timing, social context — are still poorly mapped. The unresolved tension is whether therapeutic protocols can be designed to reliably isolate the beneficial windows without the field first generating better data on who is most vulnerable.

Studies in this issue

Primary sources used for this newsletter.

Adolescent use of the psychedelic 25C-NBOMe in rats leads to lasting avoidance behavior linked to disrupted coordination between memory and decision-making brain areas
main storyNature neuroscience2026-07-20PMID 42477457
Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers.
key findingMolecular psychiatry2026-07-24PMID 42498781
MDMA as an early treatment after trauma in an animal model of PTSD
key findingProgress in neuro-psychopharmacology & biological psychiatry2026-07-24PMID 42498117
Social rank influences behavior and gene activity responses to long-term stress and ketamine in male mice
key findingiScience2026-07-24PMID 42495548
Real-world results of nasal esketamine and intravenous ketamine treatments for hard-to-treat depression in a community clinic
key findingFrontiers in psychiatry2026-07-24PMID 42494735
A new psychedelic quipazine-like drug designed for therapy with possibly fewer side effects
key findingScience signaling2026-07-21PMID 42479815
Factors influencing how British Columbia's drug decriminalization pilot is carried out: A detailed review
key findingThe International journal on drug policy2026-07-21PMID 42480418